Pluristem's PLX Cells Demonstrate Efficacy in Preclinical Study for Graft Versus Host Disease
Pluristem Therapeutics Inc., a leading developer of placenta-based cell therapies, announced today that the company’s PLacental eXpanded (PLX) cells demonstrated efficacy in a preliminary animal experiment for the treatment of Graft versus Host Disease (GvHD) following bone marrow transplantation (BMT). The results showed that PLX cells, regardless of their administration route, intravenous (IV) or intramuscular (IM), demonstrated a statistically significant improvement (p<0.05) in the GvHD score. Following interest from leading medical institutions, Pluristem is investigating a potential cooperation to bring...
View full press release